Iron, lipids, and risk of cancer in the Framingham offspring cohort

American Journal of Epidemiology

Volumn 161, Issue 12, 2005, Pages 1115-1122

  Mainous III, Arch G ^a   Wells, Brian J ^b   Koopman, Richelle J ^a   Everett, Charles J ^a   Gill, James M ^c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cohort studies; Iron; Lipids; Neoplasms

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CANCER; HEALTH RISK;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; HUMAN; IRON BLOOD LEVEL; LIPID BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; SURVIVAL RATE; TRACHEA CANCER;

ADULT; AGE DISTRIBUTION; AGED; COHORT STUDIES; COMORBIDITY; HUMANS; INCIDENCE; IRON; LIPIDS; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SEX DISTRIBUTION; SMOKING; SURVIVAL ANALYSIS; UNITED STATES;

EID: 20544438985     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi131     Document Type: Article

References (39)

1. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? Free Radic Biol Med 2002; 32:968-74.
2. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol 2000;32:157-70.
3. Poulsen HE, Prieme H, Loft S. Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev 1998;7:9-16.
4. Hristozov D, Gadjeva V, Vlaykova T, et al. Evaluation of oxidative stress in patients with cancer. Arch Physiol Biochem 2001;109:331-6.
5. Smith C, Mitchinson MJ, Aruoma OI, et al. Stimulation of lipid peroxidation and hydroxyl-radical generation by contents of human atherosclerotic lesions. Biochem J 1992;286:901-5.
6. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984;74:1890-4.
7. Ferretti G, Bacchetti T, Bicchiega V, et al. Effect of human Apo AIV against lipid peroxidation of very low density lipoproteins. Chem Phys Lipids 2002;114:45-54.
8. Hirofumi A, Kashiwagi S, Nagasaka Y, et al. Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arch Biochem Biophys 1999;367:1-8.
9. Mackness MI, Arrol S, Abbott C, et al. Protection of low-density lipoprotein against oxidative modification by high-denisty lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
10. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-denisty lipoprotein. FEBS Lett 1991;286:152-4.
11. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid perxoidation. Atherosclerosis 1995;115:243-53.
12. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83.
13. Glei M, Latunde-Dada GO, Klinder A, et al. Iron-overload induces oxidative DNA damage in the human colon carcinoma cell line HT29 clone 19A. Mutat Res 2002;519:151-61.
14. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
15. Fischer JG, Glauert HP, Yin T, et al. Moderate iron overload enhances lipid peroxidation in livers of rats, but does not affect NF-κB activation induced by the peroxisome proliferator, Wy-14,643. J Nutr 2002;132:2525-31.
16. Johnson S. The possible crucial role of iron accumulation combined with low tryptophan, zinc and manganese in carcinogenesis. Med Hypotheses 2001;57:539-43.
17. Knekt P, Reunanen A, Takkunen H, et al. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-82.
18. Stevens RG, Graubard BI, Micozzi MS, et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-9.
19. Rywik SL, Manolio TA, Pajak A, et al. Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). Am J Cardiol 1999;84:540-8.
20. Baptiste MS, Nasca PC, Doyle JT, et al. Cholesterol and cancer in a population of male civil services workers. Int J Epidemiol 1992;21:16-22.
21. Sharp SJ, Pocock SJ. Time trends in serum cholesterol before cancer death. Epidemiology 1997;8:120-2.
22. Eicholzer M, Stahelin HB, Gutzwiller F, et al. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr 2000;71:569-74.
23. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979;110: 281-90.
24. Adamson JW. Iron deficiency and other hypoproliferative anemias. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. Harrison's principles of internal medicine. 16th ed. Part 5, sect 2, chap 90. New York, NY: The McGraw-Hill Companies, Inc, 2005. (http://harrisons.accessmedicine.com/server-Java/Arknoid/ amed/harrisons/co_chapters/ch105/chl05_p01.html).
25. Abell LL, Levy BB, Brodie BB, et al. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem 1952;195: 357-66.
26. Lipid Research Clinics Program. Manual of laboratory operations. Vol 1. Lipid and lipoprotein analysis. Washington, DC: US Government Printing Office, 1974. (DHEW publication no. (NIH) 75-628).
27. Anderson KM, Wilson PW, Garrison RJ, et al. Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample. The Framingham Offspring Study. Atherosclerosis 1987;68:59-66.
28. Schoenfeld D. Partial residuals for the proportional hazards model. Biometrika 1982;69:51-5.
29. National Center for Chronic Disease Prevention and Health Promotion. Smoking prevalence among U.S. adults, fact sheet, July 2002. Washington, DC: National Center for Chronic Disease Prevention and Health Promotion, 2005. (http://www.cdc.gov/tobacco/research_data/adults_prev/prevali.htm).
30. Toyokuni S. Oxidative stress and cancer: the role of redox regulation. Biotherapy 1998;11:147-54.
31. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 1998;19:A40-4.
32. Mohr D, Stocker R. Radical-mediated oxidation of isolated human very-low-density lipoprotein. Arterioscler Thromb 1994;14:1186-92.
33. Wells BJ, Mainous AG 3rd, King DE, et al. The combined effect of transferrin saturation and low density lipoprotein on mortality. Fam Med 2004;36:324-9.
34. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
35. Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-52.
36. Wu T, Sempos CT, Freudenheim JL, et al. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195-201.
37. Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol 2004;22: 2388-94.
38. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90:635-7.
39. Witte DL, Crosby WH, Edwards CQ, et al. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.